瑞舒伐他汀对冠心病患者心功能、血脂水平的影响观察

Observation on effect of rosuvastatin on heart function and blood lipids level in patients with coronary heart disease

目的观察瑞舒伐他汀对冠心病患者心功能和血脂水平的影响。方法 102例冠心病患者,随机分为对照组和观察组,每组51例。对照组给予常规治疗,观察组在对照组基础上给予瑞舒伐他汀治疗。比较两组患者治疗前后心功能指标及血脂指标。结果治疗后两组患者左室收缩末期内径(LVESD)、左室舒张末期内径(LVEDD)、左心室收缩末期容量(LVESV)、左心室舒张末期容量(LVEDV)、左心室射血分数(LVEF)水平均优于治疗前,差异有统计学意义(P<0.05)。治疗后观察组患者LVESD、LVEDD、LVESV、LVEDV、LVEF分别为(32.8±5.0)mm、(47.9±7.2)mm、(82.6±12.6)ml、(160.2±12.9)ml、(39.8±6.3)%,均优于对照组的(36.1±9.8)mm、(52.2±9.1)mm、(101.6±18.7)ml、(176.5±11.7)ml、(36.1±5.1)%,差异有统计学意义(P<0.05)。治疗后两组患者血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)水平均优于治疗前,且观察组优于对照组,差异有统计学意义(P<0.05)。结论瑞舒伐他汀可进一步改善患者心功能指标和血脂指标,值得临床推广使用。

Objective To observe the effect of rosuvastatin on heart function and blood lipids level in patients with coronary heart disease. Methods A total of 102 patients with coronary heart disease were randomly divided into control group and observation group, with 51 cases in each group. The control group received conventional treatment, and the observation group received rosuvastatin for treatment on the basis of the control group. The heart function and blood lipid indicators were compared between the two groups before and after treatment. Results After treatment, both groups had better left ventricular end-systolic diameter（LVESD）, left ventricular end-diastolic dimension（LVEDD）, left ventricular end systolic volume（LVESV）, left ventricular end diastolic volume（LVEDV）, left ventricular ejection fraction（LVEF） than before treatment, and the difference was statistically significant（P〈0.05）. After treatment, the observation group had better LVESD, LVEDD, LVESV, LVEDV, LVEF respectively as（32.8±5.0） mm,（47.9±7.2） mm,（82.6±12.6） ml,（160.2±12.9） ml and（39.8±6.3）% than（36.1±9.8） mm,（52.2±9.1） mm,（101.6±18.7） ml,（176.5±11.7） ml and（36.1±5.1）% in the control group, and their difference was statistically significant（P〈0.05）. After treatment, both groups had better total cholesterol（TC）, triglyceride（TG）, high-density lipoprotein cholesterol（HDL-C） and low density lipoprotein cholesterol（LDL-C） than before treatment, and the observation group was better than the control group. Their difference was statistically significant（P〈0.05）. Conclusion Rosuvastatin can further improve the cardiac function and blood lipid indicators, and is worthy of clinical promotion and application.